BioCentury | Jul 26, 2010
Company News

Antitope, Pikamab deal

...Antitope will use its EpiScreen immunogenicity testing technology to profile mAbs from Pikamab for cancer and...
...for cancer and autoimmune indications. Further details were not disclosed. Antitope Ltd. , Babraham, U.K. Pikamab...
BioCentury | Jul 5, 2010
Company News

Pikamab, University of Alabama at Birmingham Research Foundation deal

...in the cytoplasmic domain of CD89 (Fc alpha receptor type 1) in IgA-mediated autoimmune disease. Pikamab...
...for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), respectively. Financial terms were not disclosed. Pikamab...
BioCentury | Oct 26, 2009
Company News

Pikamab Inc., Hospital for Special Surgery deal

...FCGR2B ) promoter polymorphisms to determine the occurrence and susceptibility patterns of lupus in humans. Pikamab...
...polymorphisms to predict how patients respond to treatment and to determine disease progression and severity. Pikamab...
...conducting validation testing of Therasight and expects the CLIA tests to be available in 2010. Pikamab...
Items per page:
1 - 3 of 3
BioCentury | Jul 26, 2010
Company News

Antitope, Pikamab deal

...Antitope will use its EpiScreen immunogenicity testing technology to profile mAbs from Pikamab for cancer and...
...for cancer and autoimmune indications. Further details were not disclosed. Antitope Ltd. , Babraham, U.K. Pikamab...
BioCentury | Jul 5, 2010
Company News

Pikamab, University of Alabama at Birmingham Research Foundation deal

...in the cytoplasmic domain of CD89 (Fc alpha receptor type 1) in IgA-mediated autoimmune disease. Pikamab...
...for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), respectively. Financial terms were not disclosed. Pikamab...
BioCentury | Oct 26, 2009
Company News

Pikamab Inc., Hospital for Special Surgery deal

...FCGR2B ) promoter polymorphisms to determine the occurrence and susceptibility patterns of lupus in humans. Pikamab...
...polymorphisms to predict how patients respond to treatment and to determine disease progression and severity. Pikamab...
...conducting validation testing of Therasight and expects the CLIA tests to be available in 2010. Pikamab...
Items per page:
1 - 3 of 3